.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Chubb
Novartis
Accenture
Boehringer Ingelheim
Moodys
Covington
US Department of Justice
Teva

Generated: December 16, 2017

DrugPatentWatch Database Preview

Ticagrelor - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ticagrelor and what is the scope of ticagrelor patent protection?

Ticagrelor
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ticagrelor has two hundred and fifty patent family members in forty-eight countries and twelve supplementary protection certificates in eleven countries.

There are nineteen drug master file entries for ticagrelor. Three suppliers are listed for this compound.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeYYY► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-001Jul 20, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsBRILINTAticagrelorTABLET;ORAL022433-001Jul 20, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: ticagrelor

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,974,868 Compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ticagrelor

Country Document Number Estimated Expiration
Iceland2609► Subscribe
Portugal1289992► Subscribe
China1817883► Subscribe
Ukraine73181► Subscribe
Philippines12013501627► Subscribe
Slovenia2056832► Subscribe
Canada2296665► Subscribe
Indonesia29927► Subscribe
Brazil0111328► Subscribe
Slovakia287817► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TICAGRELOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1135391/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
6Finland► Subscribe
C0016France► SubscribePRODUCT NAME: TICAGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/10/655/001 DU 20101203; REGISTRATION NO/DATE AT EEC: EU/1/10/655/001-006 DU 20101203
90009-9Sweden► SubscribePRODUCT NAME: TICAGRELOR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV; REG. NO/DATE: EU/1/10/655/001-006 20101203
C/GB11/016United Kingdom► SubscribePRODUCT NAME: TICAGRELOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/10/655/001 20101203; UK EU/1/10/655/002 20101203; UK EU/1/10/655/003 20101203; UK EU/1/10/655/004 20101203; UK EU/1/10/655/005 20101203; UK EU/1/10/655/006 20101203
2011004,C1135391Lithuania► SubscribePRODUCT NAME: TICAGRELORUM; REGISTRATION NO/DATE: EU/1/10/655/001 2010 12 03 EU/1/10/655/002 2010 12 03 EU/1/10/655/003 2010 12 03 EU/1/10/655/004 2010 12 03 EU/1/10/655/005 2010 12 03 EU/1/10/655/00 20101203
2011 00013Denmark► Subscribe
11/012Ireland► SubscribePRODUCT NAME: TICAGRELOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/10/655/001-006 20101203
2011004Lithuania► SubscribePRODUCT NAME: TICAGRELORUM; REGISTRATION NO/DATE: EU/1/10/655/001 2010 12 03 EU/1/10/655/002 2010 12 03 EU/1/10/655/003 2010 12 03 EU/1/10/655/004 2010 12 03 EU/1/10/655/005 2010 12 03 EU/1/10/655/00 20101203
00485Netherlands► SubscribePRODUCT NAME: TICAGRELOR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/10/655/001-006 20101203
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chubb
US Army
Baxter
Novartis
Express Scripts
Covington
Chinese Patent Office
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot